Sutro Biopharma Inc
NASDAQ:STRO
Sutro Biopharma Inc
Revenue
Sutro Biopharma Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sutro Biopharma Inc
NASDAQ:STRO
|
Revenue
$153.7m
|
CAGR 3-Years
53%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Sutro Biopharma Inc's Revenue?
Revenue
153.7m
USD
Based on the financial report for Dec 31, 2023, Sutro Biopharma Inc's Revenue amounts to 153.7m USD.
What is Sutro Biopharma Inc's Revenue growth rate?
Revenue CAGR 5Y
32%
Over the last year, the Revenue growth was 127%. The average annual Revenue growth rates for Sutro Biopharma Inc have been 53% over the past three years , 32% over the past five years .